Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 3.65B | 3.54B | 3.09B | 3.38B | 2.68B |
Gross Profit | 1.74B | 1.71B | 1.42B | 1.42B | 1.20B |
EBITDA | 893.87M | 913.55M | 794.03M | 795.27M | 787.26M |
Net Income | 460.80M | 530.43M | 448.06M | 468.13M | 557.24M |
Balance Sheet | |||||
Total Assets | 6.85B | 6.50B | 5.48B | 5.01B | 5.01B |
Cash, Cash Equivalents and Short-Term Investments | 1.66B | 1.08B | 960.11M | 1.57B | 1.74B |
Total Debt | 1.32B | 1.27B | 568.45M | 233.87M | 123.93M |
Total Liabilities | 2.80B | 2.54B | 1.70B | 1.33B | 1.36B |
Stockholders Equity | 4.03B | 3.97B | 3.78B | 3.67B | 3.65B |
Cash Flow | |||||
Free Cash Flow | 403.85M | 966.59M | 273.38M | 282.47M | 511.94M |
Operating Cash Flow | 527.30M | 1.10B | 653.69M | 598.55M | 773.29M |
Investing Cash Flow | -306.29M | -1.21B | -1.18B | -280.05M | -190.78M |
Financing Cash Flow | -471.60M | 227.99M | -90.43M | -482.92M | -590.33M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | HK$52.07B | 13.32 | 22.98% | 5.67% | 32.49% | 37.50% | |
74 Outperform | €4.48B | 8.96 | 11.40% | 19.25% | 1.38% | -14.80% | |
73 Outperform | HK$13.21B | 8.44 | 13.55% | 11.92% | 13.03% | 22.23% | |
73 Outperform | HK$1.04B | 35.06 | 2.07% | 1.10% | -14.59% | 29.36% | |
69 Neutral | HK$515.45M | 3.74 | 6.38% | 2.13% | 7.08% | 190.74% | |
56 Neutral | HK$23.71B | 3.90 | -1.57% | 6.72% | 0.06% | -64.88% | |
50 Neutral | $2.35B | 10.50 | 2.27% | 15.20% | -0.16% | -189.58% |
China Lilang Limited has announced the appointment of Prof. Liao Jianwen and Prof. Jiang Zhan as independent non-executive directors. Both professors have confirmed their independence according to the Listing Rules, with no financial or other interests in the company’s business, ensuring their impartiality in governance.
The most recent analyst rating on (HK:1234) stock is a Buy with a HK$4.85 price target. To see the full list of analyst forecasts on China Lilang Ltd. stock, see the HK:1234 Stock Forecast page.
China Lilang Ltd. announced that all proposed ordinary resolutions at its Annual General Meeting held on April 30, 2025, were approved by shareholders. Key resolutions included the approval of financial statements, declaration of dividends, re-election of directors, and granting mandates for share issuance and repurchase, reflecting strong shareholder support and strategic alignment for future growth.
China Lilang Ltd. reported a high-single-digit growth in retail sales for its LILANZ products in the first quarter of 2025 compared to the same period in 2024. This operational update, based on preliminary unaudited data, suggests a positive trend in the company’s retail performance, though stakeholders are advised to exercise caution as the data is subject to change.